Skip to main content

Table 1 Patient characteristics

From: Association of microRNA-224-3p and microRNA-155-5p expressions with plasma long pentraxin 3 concentration and coronary microvascular obstruction following primary angioplasty for acute ST-segment elevation myocardial infarction

Variables

All patients (N = 217)

miR-224-3p ≥ median (N = 109)

miR-224-3p < median (N = 108)

P

miR-155-5p ≥ median (N = 109)

miR-155-5p < median (N = 108)

P

Clinical characteristics

 Age (y)

54 (47–63)

55 (48–63)

53 (46–63)

0.38

56 (48–67)

52 (46–63)

0.22

 Male, n (%)

191 (88)

99 (90.8)

92 (85.2)

0.20

93 (85.3)

98 (90.7)

0.21

 Body mass index, kg/m2

24.2 (22.2–26.9)

23.8 (21.5–26.8)

24.8 (22.5–27.1)

0.33

24.2(21.4–27.1)

23.8 (22.4–26.6)

0.62

CAD risk factors, n (%)

 Hypertension

129 (59.4)

68 (62.4)

61 (56.5)

0.37

66 (60.6)

63 (58.3)

0.73

 Diabetes mellitus

65 (30)

31 (28.4)

34 (31.5)

0.62

30 (27.5)

35 (32.4)

0.43

 Dyslipidemia

53 (24.4)

29 (26.6)

24 (22.2)

0.45

28 (25.7)

25 (23.1)

0.66

 Smoking

168 (77.4)

86 (78.9)

82 (75.9)

0.60

81 (74.3)

87 (80.6)

0.27

 Family History

34 (15.7)

14 (12.8)

20 (18.5)

0.25

19 (17.6)

15 (13.8)

0.43

Symptom onset > 6 h, n (%)

105 (48.4)

48 (44.0)

57 (52.8)

0.19

48 (44.0)

57 (52.8)

0.19

Anterior MI, n (%)

112 (51.6)

56 (51.4)

56 (51.9)

0.94

58 (53.2)

54 (50.0)

0.63

TIMI risk score > 4, n (%)

61 (28.1)

31 (28.4)

30 (27.8)

0.91

33 (30.3)

28 (25.9)

0.47

Killip class II–IV, n (%)

41 (18.9)

17 (15.6)

24 (22.2)

0.21

17 (15.6)

24 (22.2)

0.21

Medication at 24 h, n (%)

 Salicylic acid

217 (100)

109 (100)

108 (100)

NA

109 (100)

108 (100)

NA

 Clopidogrel

164 (75.6)

83 (76.1)

81 (75.0)

0.84

81 (74.3)

83 (76.9)

0.66

 Ticagrelor

53 (24.4)

26 (23.9)

27 (25)

0.84

28 (25.7)

25 (23.1)

0.66

   ACE-inhibitor

60 (27.6)

24 (22.0)

36 (33.3)

0.06

28 (25.7)

32 (29.6)

0.51

   Beta-blocker

4 (1.8)

2 (1.8)

1 (1.9)

1.00

1 (0.9)

3 (2.8)

0.30

   Statin

212 (97.7)

106 (97.2)

106 (98.1)

1.00

107 (98.2)

105 (97.2)

0.68

Anticoagulation, n (%)

66 (30.4)

35 (32.1)

31 (28.7)

0.58

33 (30.2)

33 (30.5)

0.96

Medications at discharged, n (%)

 Salicylic acid

214 (28.6)

108 (99.1)

106 (98.1)

0.62

108 (99.1)

106 (98.1)

0.62

 Clopidogrel

164 (75.6)

86 (78.9)

78 (72.2)

0.25

82 (75.9)

82 (75.9)

0.90

 Ticagrelor

52 (24.1)

23 (21.6)

29 (26.9)

0.34

27 (24.8)

25 (23.4)

0.80

 ACE-inhibitor

189 (87.1)

95 (87.2)

94 (87.0)

0.97

95 (87.2)

94 (87.0)

0.97

 Beta-blocker

188 (86.2)

95 (87.2)

93 (86.1)

0.81

96 (88.1)

92 (85.2)

0.53

 Statin

217 (100)

109 (100)

108 (100)

NA

109 (100)

108 (100)

NA

Echocardiography data

 LVEF, (%)

48 (40–56)

48 (41–56)

48 (40–56)

0.36

50 (41–57.7)

46 (39–55)

0.02

Laboratory characteristics

 Hemoglobin, g/dl

14.4 (13–15.4)

14.6 (13.3–15.5)

13.9 (12.8–15.2)

0.48

14.3 (13.1–15.4)

14.6 (13–15.3)

0.30

 Leukocyte count, /ul

13,230 (11,050–16,130)

14,090 (11,140–15,990)

12,905 (10,962.5–16,265)

0.68

13,570 (10,992.5–16,255)

13,230 (11,250–16,130)

0.64

 Baseline creatinine > 1.3 mg/dl, n (%)

38 (16.6)

13 (11.9)

23 (21.3)

0.06

18 (16.5)

18 (16.7)

0.97

 Admission blood glucose level, mg/dl

141 (117–201)

138 (115–195)

144.5 (118.2–207.2)

0.44

135 (115–199.7)

144 (119–202)

0.11

 Initial Troponin T, ng/L

398 (155–1021)

418 (168–1714)

389 (139.2–691)

0.16

319 (152.2–1256)

417 (155–962)

0.79

Primary PCI characteristics

 Baseline TIMI flow, n (%)

   0

160 (73.7)

77 (70.6)

83 (76.9)

0.29

77 (70.6)

83 (76.9)

0.29

   1

11 (5.1)

5 (4.6)

6 (5.6)

0.74

6 (5.5)

5 (4.6)

0.76

   2

30 (13.8)

19 (17.4)

11 (10.2)

0.12

17 (15.6)

13 (12.0)

0.44

   3

16 (7.4)

8 (7.3)

8 (7.4)

0.98

9 (8.3)

7 (6.5)

0.61

Final TIMI flow, n (%)

   0

2 (0.9)

0

2 (1.9)

0.34

1 (0.9)

1 (0.9)

1.00

   1

16 (7.4)

8 (7.3)

8 (7.4)

0.98

10 (9.2)

6 (5.6)

0.30

   2

98 (45.2)

57 (52.3)

41 (38.0)

0.03

48 (44.0)

50 (46.3)

0.73

   3

101 (46.5)

44 (40.4)

57 (52.8)

0.06

50 (45.9)

51 (47.2)

0.82

Thrombus grade 4&5, n (%)

169 (77.9)

83 (76.1)

86 (79.6)

0.53

84 (77.1)

85 (78.7)

0.77

Door-to-device time, min

64 (54–79)

67 (56–80)

63 (53–73

0.07

68 (56.5–83.7)

62 (52–73)

0.01

Procedural time, min

40 (31–55)

40 (31–57)

40 (30–52)

0.39

40 (31.2- 56.5)

41 (29–52)

0.59

Radial access, n (%)

184 (84.8)

90 (82.6)

94 (87.0)

0.35

89 (81.7)

95 (88)

0.19

Balloon predilation, n (%)

208 (95.9)

105(96.3)

103 (95.4)

0.74

103 (94.5)

105 (97.2)

0.49

Manual thrombectomy, n (%)

3 (2.8)

3 (2.8)

0

0.24

2 (1.8)

1 (0.9)

1.00

Intracoronary eptifibatide, n (%)

10 (4.6)

5 (4.6)

5 (4.6)

1.00

4 (3.7)

6 (5.6)

0.53

Infarct related artery, n (%)

 Left main

0

0

0

0

0

0

0

 LAD

113 (52.1)

56 (51.4)

57 (52.8)

0.83

57 (52.3)

56 (51.9)

0.94

 LCX

7 (3.2)

7 (6.4)

0 (0)

0.01

1 (0.9)

6 (5.5)

0.05

 RCA

97 (44.7)

46 (42.2)

51 (47.2)

0.45

46 (42.2)

51 (47.2)

0.45

Coronary involvement, n (%)

 1-Vessel disease

68 (31.1)

32 (29.4)

36 (33.3)

0.52

35 (32.1)

33 (30.6)

0.80

 2-Vessel disease

66 (30.4)

35 (32.1)

31 (28.7)

0.58

33 (30.6)

33 (30.3)

0.96

 3-Vessel disease

73 (33.6)

40 (36.7)

33 (30.6)

0.33

38 (34.9)

35 (32.4)

0.70

 Left Main disease

10 (4.6)

2 (1.8)

8 (7.4)

0.05

3 (2.8)

7 (6.5)

0.74

 Use of mechanical ventilation, n (%)

9 (4.1)

4 (3.7)

5 (4.6)

0.74

4 (3.7)

5 (4.6)

0.74

 Use of DES, n (%)

213 (98.2)

107 (98.2)

106 (98.1)

1.00

107 (98.2)

106 (9.1)

1.00

  1. CAD, coronary artery disease; MI, myocardial infarction; TIMI, thrombolysis in myocardial infarction; ACE, angiotensin converting enzyme; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; LAD, left anterior descending coronary artery; LCX, left circumflex artery; RCA, right coronary artery; DES, drug-eluting stent; NA, not analyzed